Xconomy Boston

Thermo Fisher Simplifies RNAi Delivery

Wade Roush3/10/08

Research into the use of RNA interference (RNAi) to “silence” gene activity is picking up steam (see our story two weeks ago about Alnylam’s RNAi-based treatment for RSV), but it’s still very difficult just to get RNAi agents inside cells, where they can actually do their jobs. Today Waltham, MA-based Thermo Fisher Scientific unveiled a new agent that it says can be absorbed by cultured cells directly “without the use of conventional delivery methods such as transfection reagents, viruses or electroporation.” Such an agent could significantly speed any biomedical or pharmaceutical research project in which RNAi is used to shut off specific genes, according to Thermo.

Wade Roush is Xconomy's chief correspondent and editor of Xconomy San Francisco. You can e-mail him at wroush@xconomy.com or follow him on Twitter at twitter.com/wroush.

Add Your Thoughts

You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted.
By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.